Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.38 |
| ▸ | LAP3 | P28838 | 4/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.36 |
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL3854796 | 0.85 | GSR (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1RNPEP | |
| SCHEMBL23408743 | 0.85 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL28554464 | 0.85 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL20898389 | 0.85 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Threonine SCHEMBL15323701 | 0.85 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL6130154 | 0.85 | SLC7A5 (0.51) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1964052 | 0.84 | SLC7A5 (0.39) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| D-Glutamate SCHEMBL28632361 | 0.83 | SLC1A3 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1537267 | 0.83 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL135879 | 0.83 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | claimed |
| CN-117789993-A | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-03-29 | — | — | CN | claimed |
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | disclosed |
| CN-117789993-A | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023248035-A1 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASES | PROFESSIONAL DIETETICS S.P.A. (IT) | 2023-12-28 | — | — | WO | disclosed |
| US-10329575-B2 | Regulatory sequence for plants | CERES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180223303-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160076046-A1 | PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF | CERES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9029523-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2015-01-29 | — | — | US | disclosed |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI | 2011-08-04 | — | — | US | disclosed |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES, INC (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090265815-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded therapy | ALEXANDROV NICKOLAI | 2009-10-22 | — | — | US | disclosed |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060150283-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-07-06 | — | — | US | disclosed |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-03-02 | — | — | US | disclosed |
| WO-1996030398-A1 | NOVEL AUTO ANTIGEN | MURDOCH UNIVERSITY (AU) | 1996-10-03 | — | — | WO | disclosed |
| US-4536397-A | THERAPEUTIC DRUGS AND ANIMAL FEED ADDITIVES | SANRAKU-OCEAN CO., LTD. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4456592-A | ANIMAL FEEDS | SANRAKU-OCEAN CO. (JP) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885 |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | SLC7A5 3806/4885SLC1A3 3814/4885SLC1A2 4053/4885 |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885 |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | SLC7A5 3806/4885SLC1A3 3814/4885SLC1A2 4053/4885 |
| US-20100037355-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | RNGTT, CPSF1, CPSF6 | SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885 |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.